Atgam 250MG Injection (5ml) is a therapeutic medication primarily composed of Antithymocyte Immunoglobulins, with each vial containing 250mg of this active ingredient. This drug is derived from the serum of rabbits immunized with human thymocytes, making it a polyclonal antibody preparation. Atgam is primarily used in the management of acute rejection episodes in organ transplantation, particularly in kidney transplants, and is also indicated for the treatment of aplastic anemia. By modulating the immune response, Atgam helps to reduce the activity of T-lymphocytes, which are responsible for the rejection of transplanted organs. The injection is administered intravenously, and its formulation is designed to provide a concentrated dose of immunoglobulins that can effectively target and neutralize the immune cells that contribute to transplant rejection. This makes Atgam a crucial component in the immunosuppressive therapy regimen for patients undergoing organ transplantation.